Attenuation of Pro-inflammatory Neuropeptide Levels Produced by a Cyclooxygenase-2 Inhibitor in an Animal Model of Chronic Temporomandibular Joint Inflammation

Aims: To study the neurogenic effects of a cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, in an animal model of persistent inflammation. Methods: Arthritis was induced within the temporomandibular joint (TMJ) by placing complete Freund’s adjuvant (CFA) within the superior joint space of the TMJ in adult male rats. The CFA animals were divided into 2 groups, with 1 group given the COX-2 inhibitor, rofecoxib, on days 21 through 28. Tissues were taken from experimental and control animals 4 weeks post-injection and analyzed by radioimmunoassay. The inflammatory-related neuropeptide, immunoreactive calcitonin gene-related peptide (CGRPi), was assayed from both the TMJ tissues and the trigeminal brain stem subnucleus caudalis. Results: CGRPi content was significantly increased in TMJ tissues within the untreated CFA group (72%) and was found to be effectively no different between the CFA/COX-2 group and controls. Trigeminal brain stem subnucleus caudalis CGRPi levels were not different between the groups. Conclusion: These results suggest that use of an inhibitor selective for the inducible form of cyclooxygenase enzyme, COX-2, may significantly attenuate the neurogenic component in an inflammatory TMJ animal model.

calcitonin gene-related peptide; temporomandibular joint; experimental arthritis; inflammation; complete Freund’s adjuvant

1. Fields HL. Pain. New York: McGraw-Hill, 1987.

2. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 1992;15:96–103.

3. Dray A, Urban L, Dickenson A. Pharmacology of chronic pain. Trends Pharmacol Sci 1994;15:190–197.

4. Sessle BJ, Hu JW, Yu X-M. Brain stem mechanisms of referred pain and hyperalgesia in the orofacial and temporomandibular region. In: Vecchiet L, Albe-Fessard D, Lindblom U (eds). New Trends in Referred Pain and Hyperalgesia. Amsterdam: Elsevier, 1993:59–71.

5. Woolf CJ. An overview of the mechanisms of hyperalgesia. Pulm Pharmacol 1995;8:161–167.

6. Mannion RJ, Costigan M, Decosterd I, et al. Neurotrophins: Peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Proc Natl Acad Sci USA 1999;96:9385–9390.

7. Woolf DJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-

D- aspartic acid receptor activation; Implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293–299.

8. Ma QP, Woolf CJ. Involvement of neurokinin receptors in the induction but not the maintenance of mechanical allodynia in rat flexor motoneurones. J Physiol 1995;486:769–777.

9. Woolf CJ, Mannion RJ. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 1999;353:1959–1964.

10. Ren K, Dubner R. Central nervous system plasticity and persistent pain. J Orofac Pain 1999;13:155–163.

11. Fu KY, Light AR, Maixner W. Long-lasting inflammation and long-term hyperalgesia after subcutaneious formalin injection into the rat hindpaw. J Pain 2001;2:2–11.

12. Yu XM, Sessle BJ, Vernon H, Hu JW. Effects of inflammatory irritant application to the rat temporomandibular joint on jaw and neck muscle activity. Pain 1995;60:143–149.

13. Yu XM, Sessle BJ, Haas DA, Izzo A, Vernon H, Hu JW. Involvement of NMDA receptor mechanisms in jaw electromyographic activity and plasma extravasation induced by inflammatory irritant application to temporomandibular joint region of rats. Pain 1996;68:169–178.

14. Bereiter DA, Benetti AP. Excitatory amino release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat. Pain 1996;67:451–459.

15. Carleson J, Bileviciute I, Theodorsson E, et al. Effects of adjuvant on neuropeptide-like immunoreactivity in the temporomandibular joint and trigeminal ganglia. J Orofac Pain 1997;11:195–199.

16. Swift JQ, Roszkowski MT, Alton T, Hargreaves KM. Effect of intra-articular versus systemic anti-inflammatory drugs in a rabbit model of temporomandibular joint inflammation. J Oral Maxillofac Surg 1998;56:1288–1295.

17. Carleson J, Kogner P, Bileviciute I, et al. Effects of capsaicin in temporomandibular joint arthritis in rats. Arch Oral Biol 1997;42:869–876.

18. Kapila S, Lee C, Tavakkoli Jou MR, Miller AJ, Richards DW. Development and histologic characterization of an animal modelof antigen-induced arthritis of the juvenile rabbit temporomandibular joint. J Dent Res 1995;74:1870–1879.

19. Ragno S, Morris CJ, Coumbe A, et al. PPD and hsp65 induced monoarthritis initiates spontaneous recurrent flares in Lewis rats. Ann Rheum Dis 1995;54:59–65.

20. Zhou Q, Imbe H, Dubner R, Ren K. Persistent Fos protein expression after orofacial deep or cutaneous tissue inflammation in rats: Implications for persistent orofacial pain. J Comp Neurol 1999;412:276–291.

21. Harper RP, Kerins CA, Talwar R, et al. Meal pattern analysis in response to temporomandibular joint inflammation in the rat. J Dent Res 2000;79:1704–1711.

22. Hutchins B, Spears R, Hinton RJ, Harper RP. Calcitonin gene-related peptide and substance P immunoreactivity in rat trigeminal ganglia and brainstem following adjuvant-induced inflammation of the temporomandibular joint. Arch Oral Biol 2000;45:335–345.

23. Tominaga K, Alstergren P, Kurita H, Matsukawa A, Fukuda J, Kopp S. Interleukin-1beta in antigen-induced arthritis of the rabbit temporomandibular joint. Arch Oral Biol 2001;46:539–544.

24. Alstergren P, Kopp S. Prostaglandin E2 in temporomandibular joint synovial fluid and its relation to pain and inflammatorydisorders. J Oral Maxillofac Surg 2000;58:180–186.

25. Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Relation between intra-articular temperature of the arthritic temporomandibular joint and presence of calcitonin gene-related peptide in the joint fluid. A clinical study. Acta Odontol Scand 1993;51:285–291.

26. Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Co-variation of neuropeptide Y, calcitonin gene-related peptide, substance P and neurokinin A in joint fluid from patients with temporomandibular joint arthritis. Arch OralBiol 1995;40:127–135.

27. Imbe H, Iwata K, Zhou QQ, Zou S, Dubner R, Ren K. Orofacial deep and cutaneous tissue inflammation and trigeminal neuronal activation. Implications for persistent temporomandibular pain. Cells Tissues Organs 2001;169:238–247.

28. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4”-Methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharm Exp Therap 1999;290:551–560.

29. Paxinos G, Watson C. Rat Brain in Sterotaxic Coordinates, ed 2. Sydney: Academic Press, 1986.

30. Lowry OH, Rosenbrough NJ, Farr AL, Randall MJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–275.

31. Carleson J, Alstergren P, Appelgren A, et al. A model for the study of experimentally induced temporomandibular arthritis in rats: The effect of human recombinant interleukin-1 alpha on neuropeptide-like immunoreactivity. J Orofac Pain 1996;10:9–14.

32. Siebert J, Johnson R, Harper RP, Spears R, Hinton RJ, Hutchins B. Trigeminal ganglia and brainstem levels of substance P and CGRP following chronic TMJ inflammation [abstract]. J Dent Res 1997;76:240.

33. Ahmed M, Bjurholm A, Schultzberg M, Theodorsson E, Kreicbergs A. Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis. Arthritis Rheum 1995;38:699–709.

34. Carleson J, Alstergren P, Appelgren A, et al. A model for experimental induction of acute temporomandibular joint inflammation in rats: Effects of substance P(SP) on neuropeptide-like immunoreactivity. Life Sci 1996;59:1193–1201.

35. Adachi N, Matsumoto S, Tokuhisa M, Kobayashi K, Yamada T. Antibodies against mycobacterial antigens in the synovial fluid of patients with temporomandibular disorders. J Dent Res 2000;79:1752–1757.

36. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.

37. Kopp S. Rheumatoid arthritis. In: Zarb GA, Carlsson GE, Sessle BJ, Mohl ND (eds). Temporomandibular Joint and Masticatory Muscle Disorders. Copenhagen: Munksgaard 1994:346–366.

38. Carleson J, Alstergren A, Appelgren A, et al. Effects of adjuvant on neuropeptide-like immunoreactivity in experimentally induced temporomandibular arthritis in rats. Arch Oral Biol 1996;41:705–712.

39. Smith WL, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971;231:235–237.

40. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232–235.

41. Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phase. Proc Natl Acad Sci USA 1989;86:1657–1661.

42. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737–16740.

43. Masferrer JL, Seibert K, Zweifel BS, Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992;89:3917–3921.